MARKET WIREReuters • 3h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why BLRX Stock advanced +1.00% Today — RQD Quant Desk Flash
$2.02 +1.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.02
BioLineRx Ltd. (BLRX) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $10.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BLRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BLRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, BioLineRx Ltd. (NASDAQ: BLRX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $2.02 (+1.00% 1D, market cap $10.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BLRX ranks #207 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BLRX compare to PHIO and GDTC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLRX carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PHIO (Phio Pharmaceuticals Corp.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $10.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $10.7M). Among the 5-stock peer group, BLRX leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BLRX?
▼
For BioLineRx Ltd. (BLRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #207 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.02 (-0.01%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BLRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (60/100 Composite)
🔍 WHY BLRX SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 35.3 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$2.22-9.5% Next Q
68
Q2 (-2Q)Grade C+$2.01+1.5% Next Q
65
Q3 (-1Q)Grade C+$2.04-1% Next Q
63
CurrentGrade C-$2.02+0.4% Hist 90D α
60
Trajectory: B- (68) → C- (60)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the BLRX Bull Thesis Could Fail
Even with a 60/100 (C-) score, BLRX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.39) or 200D SMA ($2.74) invalidates the momentum regime and cuts Target Base ($2.04) toward Bear Floor ($1.59).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BLRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BLRX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BLRX Stock advanced +1.00% Today — RQD Quant Desk Flash
BioLineRx Ltd. (BLRX) advanced +1.00% to $2.02, trading at 4% of its 52-week range ($1.94 – $3.95). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 4% of its 52-week range ($1.94 – $3.95) with RSI-14 at 35.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.02 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 52% gross margin and $281568 annual free cash flow.
Live BLRX Headlines & Catalysts
MARKET WIREReuters • 3h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 4h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 6h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 8h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 8h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 10h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 11h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (BLRX Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BLRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.55%▼ DESCENDING CHANNEL
2026-10-30O $1.95H $2.02L $1.94C $2.02VOL 8.8K
RES: $2.59SUP: $1.78SMA50: $2.39SMA200: $2.74
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BLRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BLRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BLRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BLRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLRX)
Health Care Rank #207 of 1016
⚔️ PHIO vs BLRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BLRX vs. PHIO, GDTC, TPST, BFRG)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, BioLineRx Ltd. (BLRX) ranks #207 by composite RQD confidence (60/100, grade C-) and #895 by equity capitalization ($10.1M). Within this direct 5-issuer industry benchmark cohort, BLRX leads on earnings valuation at N/A trailing P/E, while PHIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently leads its immediate peer cohort in composite quantitative strength at 60/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BLRX
ACTIVE
BioLineRx Ltd. | C- | 60/100 | — | — | — | +1.00% | $10.1M | Benchmark Subject |
| PHIO Phio Pharmaceuticals Corp. | D- | 42/100 | — | — | -35.0% | -5.91% | $10.0M | /phio-vs-blrx → |
| GDTC CytoMed Therapeutics Limited | D+ | 54/100 | — | — | — | -3.68% | $10.7M | /gdtc-vs-blrx → |
| TPST Tempest Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -1.24% | $10.7M | /tpst-vs-blrx → |
| BFRG Bullfrog AI Holdings Inc. | D- | 40/100 | — | 18.8% | -35.0% | +3.88% | $9.4M | /bfrg-vs-blrx → |
2. BLRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTBioLineRx Ltd. (BLRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $10.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. BLRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BLRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, BioLineRx Ltd. (NASDAQ: BLRX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $2.02 (+1.00% 1D, market cap $10.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BLRX ranks #207 in composite RQD confidence.
How does BLRX compare to PHIO and GDTC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLRX carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PHIO (Phio Pharmaceuticals Corp.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $10.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $10.7M). Among the 5-stock peer group, BLRX leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BLRX?
For BioLineRx Ltd. (BLRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #207 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BLRX trading relative to its 50-day, 200-day, and 52-week technical levels?
BLRX last traded at $2.02 (+1.00% on volume of 4,149 shares), positioning the stock -15.48% below its 50-day simple moving average ($2.39) and -26.28% below its 200-day simple moving average ($2.74). Across its 52-week range of $1.94 to $3.95, BLRX sits at the 4.0% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.77 to $2.27).
BLRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BLRX stock moving today?
Why BLRX Stock advanced +1.00% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.